WuXi Biologics (Cayman) Forecast, price target & analysts
WuXi Biologics (Cayman) Target price 2025 - Analyst rating & recommendation
WuXi Biologics (Cayman) Classifications & Recommendation:
WuXi Biologics (Cayman) Price Target
| Target Price | HKD24.13 |
| Price | HKD22.45 |
| Potential |
7.48%
register free of charge
|
| Number of Estimates | 18 |
|
18 Analysts have issued a price target WuXi Biologics (Cayman) 2026 .
The average WuXi Biologics (Cayman) target price is HKD24.13.
This is
7.48%
register free of charge
HKD35.06
56.16%
register free of charge
HKD14.05
37.42%
register free of charge
|
|
| A rating was issued by 20 analysts: 14 Analysts recommend WuXi Biologics (Cayman) to buy, 6 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the WuXi Biologics (Cayman) stock has an average upside potential 2026 of
7.48%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2027
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Billion HKD | 18.82 | 19.29 |
| 6.01% | 2.49% | |
| EBITDA Margin | 31.22% | 33.26% |
| 11.61% | 6.53% | |
| Net Margin | 19.86% | 17.83% |
| 30.98% | 10.21% |
17 Analysts have issued a sales forecast WuXi Biologics (Cayman) 2024 . The average WuXi Biologics (Cayman) sales estimate is
This results in the following potential growth metrics:
13 Analysts have issued an WuXi Biologics (Cayman) EBITDA forecast 2024. The average WuXi Biologics (Cayman) EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 WuXi Biologics (Cayman) Analysts have issued a net profit forecast 2024. The average WuXi Biologics (Cayman) net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2027
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share HKD | 0.90 | 0.83 |
| 26.83% | 7.78% | |
| P/E | 28.56 | |
| EV/Sales | 4.98 |
15 Analysts have issued a WuXi Biologics (Cayman) forecast for earnings per share. The average WuXi Biologics (Cayman) <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the WuXi Biologics (Cayman) stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
WuXi Biologics (Cayman)...
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
